Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab
Stopped Study was terminated early because of slow recruitment
Conditions
Interventions
- BIOLOGICAL: Certolizumab pegol
Sponsor
UCB Pharma